Tag: tyrosine kinase inhibitors

A perspective in Frontiers in Cardiovascular Medicine details how cardio-oncology has evolved from an ad hoc consultative niche into a ...

A systematic review details how circular RNAs regulate lung cancer progression, drive therapeutic resistance, and offer potential biomarker and treatment ...

A retrospective cohort study of 1,792 patients revealed that four metabolic–clinical subtypes predict overall survival following synchronous triple therapy for ...

A pharmacovigilance analysis of FAERS data identified distinct developmental and organ-specific adverse event signals alongside early reporting patterns for tyrosine ...

A retrospective study of electronic health records reveals diverse treatment regimens and no standard therapy for endometrial cancer following platinum ...

Oncologists documented circulating tumor DNA clearance and complete metabolic response in a patient with a rare marker-negative mediastinal seminoma harboring ...

Researchers developed an EORTC custom questionnaire tracking 50 symptoms in chronic myeloid leukemia, finding significant toxicity variations among common kinase ...

Researchers have found that the breast cancer drug abemaciclib suppresses tumor growth and halts signaling in preclinical lung cancer models ...

A single-center retrospective study linked multi-target TKIs plus immunotherapy to longer survival than bevacizumab regimens in advanced hepatocellular carcinoma.

A meta-analysis of 31 studies demonstrates that combining transarterial chemoembolization with targeted anti-VEGF agents and immune checkpoint inhibitors significantly extends ...

A decision-tree simulation shows that pathologist-initiated reflex testing for non-small cell lung cancer improves survival while lowering annual healthcare expenditures ...

A 20-year retrospective pharmacovigilance study of FAERS data identified 31,911 reports of tyrosine kinase inhibitor cardiotoxicity characterized by class-specific adverse ...

A case report documents nine months of stable disease in a patient with metastatic GIST treated with pembrolizumab after failing ...

Researchers have discovered that the RNA-binding protein HuR promotes lenvatinib resistance in hepatocellular carcinoma by stabilizing GPX4 and repressing ferroptotic ...

A systematic review and meta-analysis of 25 clinical trials found that MET tyrosine kinase inhibitors achieved a 49 percent objective ...

A disproportionality analysis of the FDA Adverse Event Reporting System reveals distinct cutaneous toxicity signals between immune checkpoint inhibitors and ...

A newly reported clinical case describes the concurrent baseline presence of the Philadelphia chromosome, del(5q), and monosomy 7 in accelerated-phase ...

A phase 2 basket trial found oral ponatinib did not meet its primary endpoint in solid tumors with FGFR alterations, ...

A systematic review indicates that the allosteric inhibitor asciminib achieves superior molecular response rates and lower treatment discontinuation compared to ...

Clinicians have reported a case of probable Stevens–Johnson syndrome linked to taletrectinib in a patient with ROS1-positive non-small cell lung ...